Selvita And Orion Pharma co-develop Alzheimer compound
Kraków/ Espoo – Finland’s Orion Corp and Polish drugmaker Selvita have agreed to collaborate on research and development of Selvita’s oral Alzheimer compound SEL103 program in multiple cognitive disorder indications. According to the global development and marketing agreement, Selita will receive an initial up-front payment from Orion, as well as research funding and milestones. Selvita will be responsible for compound screening and selection on the programme and Orion will take over the pre-clinical and clinical development as well as further commercialisation. The companies are planning to conduct a broad-based global research and development programme which will combine the resources of Orion’s experienced CNS research and development team with Selvita’s competencies in discovery chemistry and biology assays.